Arrowhead Pharmaceuticals' SWOT analysis: stock poised for potential breakthrough
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), a biopharmaceutical company with a market capitalization of $2.68 billion ...
Business Wire13d
Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has accepted ...
Arrowhead Forensics & GA-EMS Partnership Launches New Full Spectrum Imaging System For Crime Scene Evidence Capture
FSIS-CSE in use. Industry leaders partner through product development, brand recognition and global distribution competency LENEXA, KS, ...
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 10, 2025, at 4:30 p.m. ET to discuss its financial results for the fiscal ...